![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » The Medicines Company Discontinues Development of MDCO-216
The Medicines Company Discontinues Development of MDCO-216
The Medicines Company has terminated the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.
Data from the pilot trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development.
Upcoming Events
-
21Oct